GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent ...

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...